1. Home
  2. IMUX vs PROV Comparison

IMUX vs PROV Comparison

Compare IMUX & PROV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMUX
  • PROV
  • Stock Information
  • Founded
  • IMUX 2016
  • PROV 1956
  • Country
  • IMUX United States
  • PROV United States
  • Employees
  • IMUX N/A
  • PROV N/A
  • Industry
  • IMUX Biotechnology: Pharmaceutical Preparations
  • PROV Savings Institutions
  • Sector
  • IMUX Health Care
  • PROV Finance
  • Exchange
  • IMUX Nasdaq
  • PROV Nasdaq
  • Market Cap
  • IMUX 102.2M
  • PROV 107.5M
  • IPO Year
  • IMUX N/A
  • PROV 1996
  • Fundamental
  • Price
  • IMUX $1.09
  • PROV $14.45
  • Analyst Decision
  • IMUX Strong Buy
  • PROV Hold
  • Analyst Count
  • IMUX 7
  • PROV 1
  • Target Price
  • IMUX $12.67
  • PROV $16.00
  • AVG Volume (30 Days)
  • IMUX 555.7K
  • PROV 7.3K
  • Earning Date
  • IMUX 05-07-2025
  • PROV 04-28-2025
  • Dividend Yield
  • IMUX N/A
  • PROV 3.88%
  • EPS Growth
  • IMUX N/A
  • PROV N/A
  • EPS
  • IMUX N/A
  • PROV 0.91
  • Revenue
  • IMUX N/A
  • PROV $38,443,000.00
  • Revenue This Year
  • IMUX N/A
  • PROV $2.30
  • Revenue Next Year
  • IMUX N/A
  • PROV $9.89
  • P/E Ratio
  • IMUX N/A
  • PROV $15.89
  • Revenue Growth
  • IMUX N/A
  • PROV N/A
  • 52 Week Low
  • IMUX $0.92
  • PROV $12.01
  • 52 Week High
  • IMUX $2.11
  • PROV $16.70
  • Technical
  • Relative Strength Index (RSI)
  • IMUX 46.81
  • PROV 47.80
  • Support Level
  • IMUX $1.18
  • PROV $13.86
  • Resistance Level
  • IMUX $1.28
  • PROV $14.50
  • Average True Range (ATR)
  • IMUX 0.07
  • PROV 0.40
  • MACD
  • IMUX -0.00
  • PROV 0.06
  • Stochastic Oscillator
  • IMUX 6.00
  • PROV 84.97

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

About PROV Provident Financial Holdings Inc.

Provident Financial Holdings Inc is a holding company of Provident Savings Bank, F.S.B. Through the bank, it is engaged in providing community and mortgage banking services to consumers and small to mid-sized businesses in the Inland Empire region of Southern California. The company's business segment is Bank. The Bank's activities include attracting deposits, offering banking services, and originating and purchasing single-family, multi-family, commercial real estate, construction, and other mortgage loans and, to a lesser extent, commercial business and consumer loans held for investment.

Share on Social Networks: